The executives of listed pharmaceutical companies are "exchanged": some people leave and some people take office

The change of executive positions in listed pharmaceutical companies has always been a topic of concern in the industry
.
According to incomplete statistics, from the beginning of 2022 to February 24, 28 senior executives of pharmaceutical companies have temporarily left or left the pharmaceutical industry
.
Recently, another group of pharmaceutical company executives have undergone a major “exchange”, involving Hengrui Medicine, Nuotai Bio, Chengdu Pioneer, Connecticut Biomedicine and other pharmaceutical companies
.
Hengrui Medicine: Deputy General Manager Resigns On February 25, Zhang Yuehong, Deputy General Manager of Hengrui Medicine, resigned due to personal reasons
.
The announcement stated that after resigning from the above-mentioned positions, Zhang Yuehong no longer holds any positions in the company, and the related work in charge has been handed over.
This personnel change will not affect the normal development of the company's related work
.
The company is a pharmaceutical and health enterprise engaged in pharmaceutical innovation and high-quality pharmaceutical R&D, production and promotion.
Its main business involves pharmaceutical R&D, production and sales
.
According to the third quarterly report of Hengrui Medicine in 2021, the company's main income was 20.
199 billion yuan, a year-on-year increase of 4.
05%; the net profit attributable to the parent was 4.
207 billion yuan, a year-on-year decrease of 1.
21%
.
Nuotai Biological: Resignation of Core Technicians Nuotai Biology recently announced that Mr.
Ding Jiansheng, the company's core technical personnel, resigned recently due to personal reasons and will no longer hold any positions in the company after his resignation
.
The company stated that it has built a high-level R&D team, and the core team has rich experience in operation management and R&D of large international multinational pharmaceutical companies
.
As of the end of 2021, the number of core technical personnel of the company is 12, and as of the disclosure date of this announcement, the number of core technical personnel of the company is 11
.
The company believes that the resignation of Mr.
Ding Jiansheng will not have a significant adverse impact on the company's technology research and development, production and operation, and will not affect the company's core technology and research and development work
.
According to the data, Nuotai Bio is a biopharmaceutical enterprise whose main business is the research and development, production, sales and technical services of peptides and small molecule chemical drugs
.
The 2021 performance report shows that the company achieved an annual operating income of 642 million yuan, a year-on-year increase of 13.
23%
.
Net profit attributable to owners of the parent company was 114 million yuan, a year-on-year decrease of 7.
51%
.
Chengdu Pioneer: Resignation of core technicians On March 1, Chengdu Pioneer announced that in view of the resignation of the company's human resources director Ms.
Yuan Meng due to personal reasons, the company's board meeting reviewed and approved the "Proposal on the dismissal of Ms.
Yuan Meng's company human resources director".
, the company's board of directors agreed to dismiss Ms.
Yuan Meng as director of human resources
.
After Ms.
Yuan Meng resigned, she no longer held any positions in the company
.
As of the date of this announcement, Ms.
Yuan Meng did not directly hold the company's shares
.
The company's human resources work has been properly handed over.
The dismissal of Ms.
Yuan Meng will not affect the normal operation of the company, and there is no situation that damages the interests of the company and shareholders
.
According to the data, Chengdu Xiandao is a biotechnology company engaged in the research and development of new drugs.
The company has its own core technology and research and development capabilities, as well as the core intellectual property rights of the research and development of new drug projects
.
The 2021 performance report shows that the company achieved operating income of 316 million yuan, a year-on-year increase of 29.
62%; net profit attributable to owners of the parent company was 65.
4103 million yuan, a year-on-year increase of 2.
17%
.
Connecticut Biopharmaceuticals CMO Newly Appointed Recently, Connected Biopharmaceuticals announced that Chin Lee will be the Chief Medical Officer (CMO), effective March 1, 2022
.
It is reported that Chin Le has more than 15 years of clinical research and development experience in the biopharmaceutical industry
.
Prior to joining the company, he served as Vice President, Head of Clinical Sciences and CMO at Theravance Biopharma,
Inc.
According to the data, Connected Biomedical is a biopharmaceutical company with clinical-stage products and a global layout.
It develops innovative therapies through its self-developed T cell function regulation platform, thereby improving the quality of life of patients with chronic inflammatory diseases
.
According to the financial report for the first half of 2021, the company’s loss was 268 million yuan, and the operating loss in the same period last year was 62.
54 million yuan; the net loss was 942 million yuan, and the net loss in the same period last year was 75.
207 million yuan
.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
.